Daniel Snell, Tea Gunde, Stefan Warmuth, Bithi Chatterjee, Matthias Brock, Christian Hess, Maria Johansson, Alexandre Simonin, Fabio Mario Spiga, Christopher Weinert, Niels Kirk, Nicole Bassler, Lucia Campos Carrascosa, Naomi Flückiger, Robin Heiz, Sandro Wagen, Noreen Giezendanner, Alessandra Alberti, Yasemin Yaman, Dana Mahler, Dania Diem, Peter Lichtlen, David Urech
Mesothelin (MSLN) is an attractive immuno-oncology target, but the development of MSLN-targeting therapies has been impeded by tumor shedding of soluble MSLN (sMSLN), on-target off-tumor activity, and an immunosuppressive tumor microenvironment. We sought to engineer an antibody-based, MSLN-targeted T-cell engager (αMSLN/αCD3) with enhanced ability to discriminate high MSLN-expressing tumors from normal tissue, and activity in the presence of sMSLN. We also studied the in vivo antitumor efficacy of this molecule (NM28-2746) alone and in combination with the multifunctional checkpoint inhibitor/T-cell co-activator NM21-1480 (αPD-L1/α4-1BB)...
2023: Oncoimmunology